Answers are grounded in this paper and cite their sources.
F.S.L, male, 48 years old, hypertensive, obese, evolved with Diabetes-related kidney disease stage 5. The patient underwent hemodialysis for 2 years until he received a deceased donor kidney transplant (TxR) on February 7, 2018. Received induction with antithymocyte globulin 5.5 mg/kg and maintenance therapy with tacrolimus and mycophenolate (MPA). After transplantation, experienced recurrent secondary infection (IgG D+/R+) by cytomegalovirus (CMV), and was switched from MPA to everolimus (EVR) 3 months post TxR, achieving viremia control.
No takes yet. Share an insight, caveat, or question.
Miranda et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: